Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: A double-blind placebo-controlled randomized-controlled trial

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 7, 2012, Pages 831-839

  Pande, Chandana ^a   Kumar, Ashish ^a   Sarin, Shiv Kumar ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

ascites; chronic liver disease; cirrhosis; decompensated liver disease; small intestinal bacterial overgrowth; spontaneous bacterial peritonitis

Indexed keywords

BILIRUBIN; NORFLOXACIN; PLACEBO; PROBIOTIC AGENT; PROTEIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; ASCITES FLUID; BACILLUS COAGULANS; BACILLUS PUMILUS; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; BLOATING; CLOSTRIDIUM BUTYRICUM; CONTROLLED STUDY; CONVALESCENCE; DEATH; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG WITHDRAWAL; ENTEROCOCCUS FAECALIS; FEMALE; HEPATIC ENCEPHALOPATHY; HIGH RISK PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOTOR DYSFUNCTION; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; TREATMENT DURATION; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NORFLOXACIN; PERITONITIS; PROBIOTICS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862169315     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283537d61     Document Type: Article

References (50)

1. Conn Ho. Spontaneous peritonitis and bacteremia in laennec's cirrhosis caused by enteric organisms: a relatively common but rarely recognized syndrome. Ann Intern Med 1964; 60:568-580.
2. Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis 1998; 27:669-674, quiz 675-676.
3. Sheer TA, Runyon BA. Spontaneous bacterial peritonitis. Dig Dis 2005; 23:39-46.
4. Evans LT, Kim WR, Poterucha JJ, Kamath PS. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 2003; 37:897-901.
5. RimolaA,García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000; 32:142-153.
6. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18:353-358.
7. TitóL, Rimola A, Ginés P, Llach J, Arroyo V, Rodé s J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8:27-31.
8. Ghassemi S, Garcia-Tsao G. Prevention and treatment of infections in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21:77-93.
9. Andreu M, Sola R, Sitges-Serra A, Alia C, Gallen M, Vila MC, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993; 104:1133-1138.
10. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986; 91:1343-1346.
11. Saab S, Hernandez JC, Chi AC, Tong MJ. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009; 104:993-1001, quiz 1002.
12. Loomba R,Wesley R, Bain A, Csako G, Pucino F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol 2009; 7:487-493.
13. Ginés P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12 (4 Pt 1):716-724.
14. Grangé JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998; 29:430-436.
15. Novella M, SoláR, Soriano G, Andreu M, Gana J, Ortiz J, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997; 25:532-536.
16. Scarpellini E, Valenza V, Gabrielli M, Lauritano EC, Perotti G, Merra G, et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol 2010; 105:323-327.
17. Sandhu BS, Gupta R, Sharma J, Singh J, Murthy NS, Sarin SK. Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites. J Gastroenterol Hepatol 2005; 20:599-605.
18. Lata J, Jurankova J, Kopacova M, Vitek P. Probiotics in hepatology. World J Gastroenterol 2011; 17:2890-2896.
19. Mangell P, Nejdfors P, Wang M, Ahrné S, Weström B, Thorlacius H, et al. Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability. Dig Dis Sci 2002; 47:511-516.
20. Chiva M, Soriano G, Rochat I, Peralta C, Rochat F, Llovet T, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 2002; 37:456-462.
21. Ersöz G, Aydin A, Erdem S, Yüksel D, Akarca U, Kumanlioglu K. Intestinal permeability in liver cirrhosis. Eur J Gastroenterol Hepatol 1999; 11:409-412.
22. Lata J, Novotný I, Príbramská V, Juránková J, Fric P, Kroupa R, et al. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 2007; 19:1111-1113.
23. Stadlbauer V, Mookerjee RP, Hodges S, Wright GAK, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008; 48:945-951.
24. Sheth AA, Garcia-Tsao G. Probiotics and liver disease. J Clin Gastroenterol 2008; 42 (Suppl 2):S80-S84.
25. Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol 2010; 16:403-410.
26. Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology 1988; 95:982-988.
27. Pande C, Kumar A, Sarin SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther 2009; 29:1273-1281.
28. Cohen MJ, Sahar T, Benenson S, Elinav E, Brezis M, Soares-Weiser K. Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding. Cochrane Database Syst Rev 2009; CD004791.
29. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121:580-591.
30. Rayes N, Seehofer D, Theruvath T, Schiller RA, Langrehr JM, Jonas S, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation - a randomized, double-blind trial. Am J Transplant 2005; 5:125-130.
31. Rayes N, Seehofer D, Hansen S, Boucsein K, Müller AR, Serke S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002; 74:123-127.
32. Caruntu FA, Benea L. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. J Gastrointestin Liver Dis 2006; 15:51-56.
33. Morencos FC, de las Heras Castaño G, Martín Ramos L, López Arias MJ, Ledesma F, Pons Romero F. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1995; 40:1252-1256.
34. Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 2004; 84:282-291.
35. Mennigen R, Bruewer M. Effect of probiotics on intestinal barrier function. Ann NY Acad Sci 2009; 1165:183-189.
36. Williams NT. Probiotics. Am J Health Syst Pharm 2010; 67:449-458.
37. Quigley EMM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 2006; 130 (2 Suppl 1):S78-S90.
38. Adawi D, Molin G, Jeppsson B. Inhibition of nitric oxide production and the effects of arginine and Lactobacillus administration in an acute liver injury model. Ann Surg 1998; 228:748-755.
39. Bauer TM, Fernández J, Navasa M, Vila J, Rodé s J. Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol 2002; 36:501-506.
40. Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram U, Molin G, et al. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology 1996; 111:334-344.
41. Eizaguirre I, Urkia NG, Asensio AB, Zubillaga I, Zubillaga P, Vidales C, et al. Probiotic supplementation reduces the risk of bacterial translocation in experimental short bowel syndrome. J Pediatr Surg 2002; 37:699-702.
42. García-Urkia N, Asensio AB, Zubillaga Azpiroz I, Zubillaga Huici P, Vidales C, García-Arenzana JM, et al. Beneficial effects of Bifidobacterium lactis in the prevention of bacterial translocation in experimental short bowel syndrome. Cir Pediatr 2002; 15:162-165.
43. Zaouche A, Loukil C, De Lagausie P, Peuchmaur M, Macry J, Fitoussi F, et al. Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation, and intestinal adaptation after small-bowel resection in rats. Scand J Gastroenterol 2000; 35:160-165.
44. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37:343-350.
45. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39:1441-1449.
46. Uchida H, Yamamoto H, Kisaki Y, Fujino J, Ishimaru Y, Ikeda H. D-Lactic acidosis in short-bowel syndrome managed with antibiotics and probiotics. J Pediatr Surg 2004; 39:634-636.
47. Wiest R, Chen F, Cadelina G, Groszmann RJ, Garcia-Tsao G. Effect of Lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension. Dig Dis Sci 2003; 48:1136-1141.
48. Pereg D, Kotliroff A, Gadoth N, Hadary R, Lishner M, Kitay-Cohen Y. Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition 2011; 27:177-181.
49. Tandon P, Moncrief K, Madsen K, Arrieta MC, Owen RJ, Bain VG, et al. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Liver Int 2009; 29:1110-1115.
50. Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol 2008; 20:688-692.